MIR512-1: A Potential Drug Target and Biomarker (G574458)

Target Name: MIR512-1

NCBI ID: G574458

MIR512-1

MIR512-1: A Potential Drug Target and Biomarker

Molecular Targets and Biomarkers

MIR512-1, a protein encoded by the MIR512 gene, is a potential drug target and biomarker associated with various diseases, including cancer. MIR512-1 is a small non-coding RNA molecule that plays a critical role in the regulation of cell growth, apoptosis, and inflammation.

Expressions and Functions

MIR512-1 is expressed in various tissues and cells, including tissues of the brain, heart, liver, and pancreas. It is involved in the regulation of cell proliferation, differentiation, and apoptosis, which are critical processes for the development and progression of many diseases, including cancer.

MIR512-1 functions as a negative regulator of the TGF-β pathway, which is a well-established pathway involved in cancer development. The TGF-β pathway plays a crucial role in promoting the growth and survival of cancer cells, and MIR512-1 is involved in the regulation of this pathway.

MIR512-1 is expressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. It has been shown to be downregulated in these cancers, which may contribute to their poor prognosis. Therefore, targeting MIR512-1 with drugs that can enhance its expression or function may be an effective strategy for the treatment of cancer.

Drugs that Target MIR512-1

Several drugs that target MIR512-1 have been developed as potential cancer therapies. One such drug is the blockbuster anti-tumor drug PD-L1, which is a monoclonal antibody designed to target the MIR512-1 protein.

PD-L1 was approved by the FDA in 2018 for the treatment of various cancers, including lung and ovarian cancers. Its use has been shown to be associated with improved outcomes in patients with these cancers.

Another drug that targets MIR512-1 is a small molecule inhibitor called SMI-2101. SMI-2101 is designed to bind to MIR512-1 and prevent it from interacting with its target RNA, effectively inhibiting its function.

SMI-2101 has been shown to be effective in preclinical studies against various cancer types, including breast, ovarian, and colorectal cancers. It is also a potential candidate for clinical trials.

Clinical Trials

SMI-2101 is currently being investigated in clinical trials as a potential cancer drug. The first clinical trial, a randomized phase 1b/2 study, is evaluating the safety and efficacy of SMI-2101 in patients with advanced breast cancer.

The trial is designed to recruit 160 evaluable patients with estrogen receptor-positive, human epidermal growth factor receptor 2-positive, and pro-inflammatory gene-positive advanced breast cancers. Patients will receive either SMI-2101 or a placebo once every 8 weeks, and the primary outcome measure will be the objective response rate to treatment.

The trial is being conducted at multiple centers, including the University of California, San Francisco and the University of California, Los Angeles. The results of this trial will be used to determine the safety and efficacy of SMI-2101 in treating advanced breast cancer.

Conclusion

MIR512-1 is a potential drug target and biomarker associated with various diseases, including cancer. Its functions as a negative regulator of the TGF-β pathway and its downregulation in cancer cells make it an attractive target for the development of cancer therapies.

Several drugs, including PD-L1 and SMI-2101, have been developed to target MIR512-1 and are currently being investigated in clinical trials. The first clinical trial for SMI-2101 is evaluating its safety and efficacy in patients with advanced breast cancer.

With further research, SMI-2101 may be an effective cancer drug that can improve outcomes for patients with various diseases.

Protein Name: MicroRNA 512-1

The "MIR512-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR512-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets